Associate Professor of Medicine, Joslin Diabetes Center

Nephrology

Robert C. Stanton is an expert in the field of Nephrology. He graduated from Drexel University College of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Robert Stanton is a published doctor. He has 38 papers published. The most current publication "Importance of glucose-6-phosphate dehydrogenase activity for cell growth."

Publications

---

• Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria.
• A story of microalbuminuria and Diabetic nephropathy.
• Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease.
• Increasing glucose 6-phosphate dehydrogenase activity restores redox balance in vascular endothelial cells exposed to high glucose.
• Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes.
• Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695-696.
• Oxidative Stress and Diabetic Kidney Disease.
• A complex interplay of factors causes Diabetic nephropathy.
• Use of medications to lower urine protein level in patients with diabetic Kidney disease.
• High-normal serum uric acid increases risk of early progressive renal function loss in type 1 Diabetes: results of a 6-year follow-up.
• High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis.
• Glucose-6-phosphate dehydrogenase-deficient mice have increased Renal oxidative stress and increased albuminuria.
• Early administration of enalapril and losartan to patients with type 1 Diabetes.
• Does blood glucose control improve vascular outcomes in patients with type 2 Diabetes?
• Microangiopathy in older patients with Diabetes mellitus.
• The mentored clinical casebook project at Harvard Medical School.
• Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.
• Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat Kidney cortex.
• Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis.
• Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide.
• Suppression of interleukin-1 beta-induced nitric oxide production in RINm5F cells by inhibition of glucose-6-phosphate dehydrogenase.
• cAMP Response of vascular smooth muscle cells to bovine parathyroid hormone.
• Clinic versus home blood pressure measurements in patients With CKD.
• Blood pressure and Diabetic nephropathy.
• Intensive treatment of Diabetic nephropathy.
• A method for determination of pyridine nucleotides using a single extract.
• Importance of glucose-6-phosphate dehydrogenase activity in cell death.
• beta Amyloid does not activate the antioxidant pentose phosphate pathway Within the B12 neural cell line.
• Activation of the hexosamine pathway causes oxidative stress and abnormal embryo gene expression: involvement in Diabetic teratogenesis.
• Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation With increased enzymatic activity.
• Signal transduction proteins that associate With the platelet-derived growth factor (PDGF) receptor mediate the PDGF-induced release of glucose-6-phosphate dehydrogena...
• Importance of glucose-6-phosphate dehydrogenase activity for cell growth.
• Risk for ESRD in type 1 Diabetes remains high despite renoprotection.
• Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability.
• High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells.
• Effects of N-acetyl-cysteine on endothelial function and inflammation in patients with type 2 Diabetes mellitus.
• Definitive localization of intracellular proteins: Novel approach using CRISPR-Cas9 genome editing, With glucose 6-phosphate dehydrogenase as a model.

Schools

---

• Hahnemann University

• Oregon Health and Science University

• Brigham Womens Hospital Harvard

Procedures Preformed

---

• Arteriovenostomy for Renal Dialysis
• Hemodialysis
• Peritoneal Dialysis

Conditions Treated

---

• Acidosis
• Acute Kidney Failure
• Alkalosis
• Calcium Metabolism Disorders
• View All

Doctors Specialties

---

• Nephrology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification
• Super Doctor

Education

---

• Brigham and Women's Hospital
• Oregon Health & Science University
• Drexel University College of Medicine

Hospital

---

• Beth Israel Deaconess Medical Center

Drug Facts

---

NPI NUMBER		1073550851
NPPES Provider LastName		STANTON
NPPES Provider FirstName		ROBERT
NPPES Provider ZIPCode		022155306
NPPES Provider State		MA
Specialty Description		Nephrology
Total Claim Count		701.0
Distinct Opioid Count		1.0
Opioid Claim Count		11.0
Percent Opioid Claims		1.57

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1073550851
Last Name Of The Provider	STANTON
First Name Of The Provider	ROBERT
View All

Similar Doctors

---

	Finnian R. McCausland
	Dr. Conall M. O Seaghdha, MD
	Dr. Colm C. Magee, MD This Doctor is OpenDoctor Recommended.
	Dr. Manish R. Maski, MD This Doctor is OpenDoctor Recommended.
	Dr. Melanie P. Hoenig, MD This Doctor is OpenDoctor Recommended.
	Dr. Mario F. Rubin, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel Roseman, MD
	Dr. Ranjit K. Dhelaria, MD This Doctor is OpenDoctor Recommended.
	Dr. Navdeep Tangri, MD This Doctor is OpenDoctor Recommended.
	Dr. Osama Amro, MD This Doctor is OpenDoctor Recommended.
	Dr. Ezra Gabbay, MD This Doctor is OpenDoctor Recommended.
	Dr. Nancy P. Wu, MD This Doctor is OpenDoctor Recommended.
	Dr. Eva B. Long, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog